Calling α-synuclein a prion is scientifically justifiable.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. Structure-function relationship of alpha-synuclein fibrillar polymorphs derived from distinct synucleinopathies.Molecular systems biology · 2026
   Article
2. One organelle to rule them all: enhancement of lysosomal activity as a therapeutic modality for protein misfolding neurodegenerative diseases.Frontiers in neuroscience · 2026
   Review
3. Current insights and assumptions on α-synuclein in Lewy body disease.Acta neuropathologica · 2024
   Review
4. Prodromal Parkinson disease signs are predicted by a whole-blood inflammatory transcriptional signature in young Pink1BMC neuroscience · 2024
   Article
5. Parkinson's Disease: Cells Succumbing to Lifelong Dopamine-Related Oxidative Stress and Other Bioenergetic Challenges.International journal of molecular sciences · 2024
   Review
6. Inhibition of Protein Aggregation and Endoplasmic Reticulum Stress as a Targeted Therapy for α-Synucleinopathy.Pharmaceutics · 2023
   Review
7. Disease-Specific α-Synuclein Seeding in Lewy Body Disease and Multiple System Atrophy Are Preserved in Formaldehyde-Fixed Paraffin-Embedded Human Brain.Biomolecules · 2023
   Article
8. Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies.Frontiers in neurology · 2022
   Review
9. Is Multiple System Atrophy a Prion-like Disorder?International journal of molecular sciences · 2021
   Review
10. A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies.Acta neuropathologica · 2021
    Article
11. From Synaptic Protein to Prion: The Long and Controversial Journey of α-Synuclein.Frontiers in synaptic neuroscience · 2020
    Review
12. Variable absorption of mutational trends by prion-forming domains duringPeerJ · 2020
    Article
13. Transmissibility versus Pathogenicity of Self-Propagating Protein Aggregates.Viruses · 2019
    Review

Corrections and comments

• Comment on
  Oral and intravenous transmission of α-synuclein fibrils to mice.2019

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as